Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A pioneering academic conference will bring together, for the first time, people from all over the world dealing with the problem of poor quality medicines and their impact on public health.

Image courtesy of Shutterstock

The Medicine Quality & Public Health conference will take place at Keble College, Oxford, UK from 23-28 September 2018. It will provide a unique opportunity for health authorities, scientists, pharmacists, lawyers and international organisations to discuss the problem and outline the necessary steps to tackle the issue on a global scale.

The proliferation of poor quality medicines is an important but neglected public health problem, threatening millions of people all over the world, both in developing and wealthy countries. Although – rightly - there has been much attention to improving access to affordable medicines, there has been less emphasis on ensuring that they are good quality or not altogether falsified.

“All over the world, medicines regulatory authorities, research groups, international organisations, law enforcement agencies and other key stakeholders, including the pharmaceutical industry, are working hard to keep patients safe and to try to ensure that the benefits of modern medicine are delivered,” says Prof Paul Newton, Head of the Medicine Quality Group at the Infectious Diseases Data Observatory (IDDO), Director of the Oxford clinical research unit in Laos and the instigator of the conference.

“However, there has never been an opportunity for the diverse stakeholders involved in medicine quality and drug regulation to come together within the framework of a dedicated academic conference to share ideas and expertise. One of the event’s key objectives is to develop a consensus statement to be widely disseminated to interested parties and policy makers, establishing the conference as a turning point in our collective approach to tackling poor quality medicines.”

The conference was inspired by a successful multidisciplinary annual course on the Quality of Medical Products & Public Health, which has been held since 2015 at the London School of Hygiene & Tropical Medicine and Boston University. This year the course and conference will run sequentially, allowing participants to combine in-depth training with networking and scientific discussion.

Discounts and fellowships are available for participants from low- and middle-income countries.

If you are interested in attending the conference tickets are nearly sold out, please visit the conference website or email mqph2018@ndm.ox.ac.uk.

Similar stories

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

Daily contact COVID-19 testing for students effective at controlling transmission in schools

A study by the University of Oxford has found that daily testing of secondary school students who were in contact with someone with COVID-19 was just as effective in controlling school transmission as the current 10-day contact isolation policy.